J Neurogastroenterol Motil.  2025 Jan;31(1):28-37. 10.5056/jnm24084.

Efficacy of Amitriptyline in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis

Affiliations
  • 1Allama Iqbal Medical College, Lahore, Pakistan
  • 2Fatima Memorial Hospital, Lahore, Pakistan
  • 3Rawalpindi Medical University, Rawalpindi, Pakistan
  • 4Khawaja Muhammad Safdar Medical College, Sialkot, Pakistan
  • 5King Edward Medical University, Lahore, Pakistan
  • 6Islamic International Medical College, Rawalpindi, Pakistan
  • 7Faculty of Medicine, University of Ribeirão Preto, Ribeirão Preto, SP, Brazil
  • 8Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, SP, Brazil
  • 9Floyd D. Loop Alumni Library, Cleveland Clinic, Cleveland, OH, USA
  • 10Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA
  • 11Department of Psychiatry and Psychology, Cleveland Clinic, Cleveland, OH, USA
  • 12Department of Psychiatry, University Hospitals Medical Center, Cleveland, OH, USA

Abstract

Background/Aims
Amitriptyline is prescribed off-label for irritable bowel syndrome (IBS). We conducted a meta-analysis to assess its efficacy.
Methods
A systematic literature review was conducted until November 10, 2023, using MEDLINE, Embase, Cochrane Library, and Web of Science to study the efficacy of amitriptyline in patients with IBS. We included all randomized controlled trials that compared amitriptyline to placebo. Revised Cochrane risk-of-bias tool was used to assess the quality of studies. Meta-analyses were performed using a bivariate random-effects model. Statistical analyses were performed using R Software 4.2.3 and heterogeneity was assessed with I 2 statistics.
Results
Seven trials were included with 796 patients (61% female). Amitriptyline was associated with better treatment response (OR, 5.30; 95% CI, 2.47 to 11.39; P < 0.001), reduced Irritable Bowel Syndrome Symptom Severity Scores (MD, –50.72; 95% CI, –94.23 to –7.20; P = 0.020) and improved diarrhea (OR, 10.55; 95% CI, 2.90 to 38.41; P < 0.001). No significant difference between the 2 groups regarding the adverse effects was observed. Three trials showed an overall low risk of bias, 2 trials showed an overall high risk of bias due to randomization and missing data, and 2 trials had some concerns regarding missing data.
Conclusions
Amitriptyline was found to be well-tolerated and effective in treating IBS compared to placebo. These findings support the use of amitriptyline for the management of IBS, particularly among patients with the IBS diarrhea subtype. Future research should focus on the dose-dependent effects of amitriptyline in IBS to better guide clinicians in personalized titration regimens.

Keyword

Abdominal pain; Amitriptyline; Antidepressants; tricyclic; Diarrhea; Irritable bowel syndrome
Full Text Links
  • JNM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr